The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

Novavax Inc. jumped as US regulators fully approved its Covid vaccine, easing investors’ concerns after the clearance was ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...